Clinical Trial Search

Primary: Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1 — 0; 0; 1; 2…

Primary: Dose Escalation Analysis: Number of DLTs Observed in Evaluable Patients — 0; 0; 0 Participants

Primary: Safety and Tolerability of P218: Incidence, Severity and Relationship to the Investigational Product of Observed and Self-reported Adverse Events — 0; 0; 2; 1 Participants

Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min

Primary: Recommended Dose of Enzalutamide — 160 mg

Primary: Number of Participants With Adverse Events — 6; 4; 3; 6 Participants

Primary: Number (%) of Grade 2 or Higher AEs Regardless of Relationship to Study Drug — 1; 3 Participants

Primary: Cumulative Percentage of Administered Radioactivity Recovered in Urine — 55.4; 56.8; 55.1 percentage of radioactive dose

Primary: Maximum Observed Plasma Concentration (Cmax) of Lanadelumab — 21.91; 21.42 microgram per milliliter (ug/mL)

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide — 37400; 40000 nanogram.hour/milliliter (ng.h/mL)…

Primary: PK (Pharmacokinetic) Parameter: AUCinf of Eleclazine — 42503.2; 50064.7; 57795.9; 39173.2 h*ng/mL

Primary: Single-dose Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Palbociclib — 82.14 nanograms per milliliter (ng/mL)

Primary: Change From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5 — -254.48; -19.93; -278.78; -37.43 kilocalories (kcal) — p=0.0000

Primary: Percent Change From Baseline in Activated and Memory T Cells — NA; NA; NA; NA Percentage

Primary: Percentage of Participants With Dose Limiting Toxicities (DLT) in Cycle 1 for the Determination of the Maximum Tolerated Dose (MTD) of Volasertib — 0.0; 0.0; 16.7; 23.5…